Companion Animal Pharmaceuticals Market by Animal Type (Dogs, Cats, Horses), Route of Administration (Oral, Injectable, Topical), Indication (Antibiotics, Parasiticides), Distribution Channel (Veterinary Hospitals & Clinics) & Region - Global Forecasts to 2027

Abstract
The global companion animal pharmaceuticals market is projected to reach USD 19.6 billion by 2027

from USD 14.4 billion in 2022, at a CAGR of 6.3% during the forecast period. The Rising prevalence of zoonotic diseases, Rising demand for pet insurance due to growing animal health expenditure, Increasing R&D investments for animal healthcare, Initiatives by various government agencies and animal associations, High pet ownership rates worldwide are some of the factors driving the growth of these markets. However, Rising pet care costs, Limited number of new product developments, High cost of vaccines and complexities associated with storage, Growing resistance to antimicrobials and antibiotics are restraining the growth of this market to a certain extent.

“The dermatologic diseases segment is projected to grow at the highest CAGR in the companion animal pharmaceuticals market.”

The dermatologic diseases segment is projected to grow at the highest CAGR during the forecast period. The rising need for advanced orthopedic drugs, increasing prevalence of arthritis, and growing pet population in developed and developing countries are some of the key factors driving the growth of this segment.

“In the forecast period, the dogs segment holds the largest share in the animal type segment.”

The dogs segment accounted for the largest market share in 2021. The large share of this segment is attributed to the increasing dog population and rising ownership rate in both developed and developing countries , rising canine healthcare expenditure, increasing prevalence of zoonotic diseases and other skin allergies in dogs, and the rising number of pet insurers across the globe.

“In the forecast period, by distribution channel segment, veterinary hospitals is expected to grow at the highest CAGR in the companion animal pharmaceuticals market”

During the forecast period, the veterinary hospitals segment is expected to grow at the highest CAGR. The higher adoption of animal parasiticides, analgesic, antimicrobials and antibiotics in hospital settings, rising cases of infectious diseases, increasing number of veterinary hospitals, growing ownership rate of companion animals, and rising veterinary expenditure are some of the key factors driving the growth of this segment.

“By Region, North America holds the largest share in the companion animal pharmaceuticals market, in the forecast period”

By Region, In 2021, North America accounted for the largest share of the companion animal pharmaceuticals market in the forecast period, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The large share of North America can be attributed to the high adoption rate of companion animals such as dogs and cats, well-established base of animal health industries, rising animal adoption centers, rising cases of parasitic infections, the large number of hospitals and clinics, growing expenditure on animal health in the region and , growing pool of veterinarians.

A breakdown of the primary participants for the companion animal pharmaceuticals market referred to for this report is provided below:
•By Company Type: Tier 1–35%, Tier 2–45%, and Tier 3–20%
•By Designation: C-level–35%, Director Level–25%, and Others–40%
•By Region: North America–40%, Asia- Pacific–30%, Europe–20%, Middle East & Africa–5%, Latin America- 5%

The prominent players in the global companion animal pharmaceuticals market are Zoetis, Inc. (US), Merck & Co., Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco Animal Health Incorporated (US), Eco Animal Health Group PlC (UK), Virbac (France), Dechra Pharmaceuticals PLC (UK), Vetoquinol (France), Neogen Corporation (US), Orion Group (Finland), Zenex Animal Health India Private Limited (India), Norbrook Holdings Limited (UK), Chanelle Pharma (Ireland), HIPRA (Spain), Ceva Sante Animale (France), Tianjin Ringpu Bio-Technology Co Ltd. (China), Kyoritsu Seiyaku (Japan), Endovac Animal Health (US), Indian Immunologicals Ltd (India), Ashish Life Sciences Pvt Ltd (India), Lutim Pharma Pvt Ltd (India), Biogénesis Bagó (US), Brilliant Bio Pharma (India), Intas Pharmaceuticals (India), and Vetindia Pharmaceuticals limited (India).

Research Coverage:
This research report categorizes the companion animal pharmaceuticals market by indication, by route of administration, by animal type, by distribution channel and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the companion animal pharmaceuticals market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements. new product & service launches, mergers and acquisitions, and recent developments associated with the companion animal pharmaceuticals market. Competitive analysis of upcoming startups in the C4ISR market ecosystem is covered in this report.

Reasons to Buy the Report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall C4ISR market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report provides insights on the following pointers:
•Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global companion animal pharmaceuticals market
•Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launches in the global companion animal pharmaceuticals market
•Market Development: Comprehensive information on the lucrative emerging regions by indication, animal type, distribution channels, and region
•Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global companion animal pharmaceuticals market.
•Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products of leading players in the global companion animal pharmaceuticals market

Content
Table of Contents

1INTRODUCTION31
1.1STUDY OBJECTIVES31
1.2MARKET DEFINITION31
1.2.1INCLUSIONS AND EXCLUSIONS32
1.2.2MARKETS COVERED33
FIGURE 1COMPANION ANIMAL PHARMACEUTICALS MARKET SEGMENTATION33
1.2.3YEARS CONSIDERED33
1.3CURRENCY CONSIDERED34
TABLE 1EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD34
1.4LIMITATIONS34
1.5STAKEHOLDERS34
1.6SUMMARY OF CHANGES35
1.6.1REFINEMENTS IN SEGMENTS OF GLOBAL MARKET35
1.6.2UPDATED FINANCIAL INFORMATION/PRODUCT PORTFOLIOS OF PLAYERS35
1.6.3UPDATED MARKET DEVELOPMENTS OF PROFILED PLAYERS35
1.6.4ADDITION OF RECESSION IMPACT35
2RESEARCH METHODOLOGY36
2.1RESEARCH APPROACH36
FIGURE 2RESEARCH DESIGN36
2.1.1SECONDARY RESEARCH37
2.1.1.1Key data from secondary sources38
2.1.2PRIMARY RESEARCH38
2.1.2.1Primary sources39
2.1.2.2Key data from primary sources40
2.1.2.3Key industry insights41
2.1.2.4Breakdown of primaries42
FIGURE 3BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION42
2.2MARKET SIZE ESTIMATION42
FIGURE 4MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS43
FIGURE 5REVENUE SHARE ANALYSIS ILLUSTRATION: ZOETIS INC.43
FIGURE 6COMPANION ANIMAL PHARMACEUTICALS MARKET: SUPPLY-SIDE ANALYSIS44
FIGURE 7MARKET ANALYSIS APPROACH45
FIGURE 8EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET APPROACH45
FIGURE 9TOP-DOWN APPROACH46
FIGURE 10CAGR PROJECTIONS47
FIGURE 11COMPANION ANIMAL PHARMACEUTICALS MARKET (2022–2027): IMPACT ANALYSIS ON DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES48
2.3DATA TRIANGULATION APPROACH50
FIGURE 12DATA TRIANGULATION METHODOLOGY50
2.4MARKET SHARE ESTIMATION51
2.5STUDY ASSUMPTIONS51
2.6RISK ASSESSMENT52
2.7LIMITATIONS52
2.7.1METHODOLOGY-RELATED LIMITATIONS52
2.7.2SCOPE-RELATED LIMITATIONS52
2.8IMPACT OF RECESSION52
3EXECUTIVE SUMMARY53
FIGURE 13COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2022 VS. 2027 (USD MILLION)53
FIGURE 14COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2022 VS. 2027 (USD MILLION)54
FIGURE 15COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2022 VS. 2027 (USD MILLION)54
FIGURE 16COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2022 VS. 2027 (USD MILLION)55
FIGURE 17COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHICAL SNAPSHOT56
4PREMIUM INSIGHTS57
4.1COMPANION ANIMAL PHARMACEUTICALS MARKET OVERVIEW57
FIGURE 18INCREASING PREVALENCE OF ZOONOTIC DISEASES AND RISING PET OWNERSHIP RATES WORLDWIDE TO DRIVE MARKET57
4.2EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION AND COUNTRY (2021)58
FIGURE 19INFECTIOUS DISEASES SEGMENT IN GERMANY ACCOUNTED FOR LARGEST SHARE IN 202158
4.3COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES59
FIGURE 20CHINA & INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD59
4.4COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION (2022–2027)60
FIGURE 21ASIA PACIFIC TO WITNESS HIGHEST CAGR DURING FORECAST PERIOD60
4.5COMPANION ANIMAL PHARMACEUTICALS MARKET: DEVELOPED VS. EMERGING MARKETS60
FIGURE 22EMERGING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD60
 
5MARKET OVERVIEW61
5.1INTRODUCTION61
5.2MARKET DYNAMICS62
FIGURE 23COMPANION ANIMAL PHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES62
5.2.1MARKET DRIVERS62
5.2.1.1Rising prevalence of zoonotic diseases62
TABLE 2ANIMAL DISEASE OUTBREAKS IN ASIA PACIFIC COUNTRIES (2013–2019)63
5.2.1.2Rising demand for pet insurance due to growing animal health expenditure64
TABLE 3US: AVERAGE PREMIUM RATES (2019–2021)64
FIGURE 24CANADA: AVERAGE ANNUAL PREMIUMS (2017–2021)64
TABLE 4NORTH AMERICA: PET HEALTH INSURANCE MARKET, 2012–2021 (USD MILLION)65
5.2.1.3Increasing R&D investments for animal healthcare65
5.2.1.4Rising awareness initiatives by government agencies and animal welfare organizations66
5.2.1.5High pet ownership rates worldwide67
TABLE 5PET POPULATION, BY ANIMAL, 2014–2020 (MILLION)67
TABLE 6MARKET DRIVERS: IMPACT ANALYSIS68
5.2.2MARKET RESTRAINTS68
5.2.2.1Rising pet care costs68
FIGURE 25US: PET INDUSTRY EXPENDITURE, 2010–202069
5.2.2.2Limited number of novel pharmaceuticals for veterinary care69
5.2.2.3High cost of vaccines and complexities associated with storage69
5.2.2.4Growing resistance to antimicrobials and antibiotics70
TABLE 7MARKET RESTRAINTS: IMPACT ANALYSIS71
5.2.3MARKET OPPORTUNITIES71
5.2.3.1Lucrative growth opportunities in emerging markets71
5.2.3.2Growing prevalence of chronic animal diseases72
5.2.3.3Rising technological advancements in vaccine manufacturing72
TABLE 8MARKET OPPORTUNITIES: IMPACT ANALYSIS73
5.2.4MARKET CHALLENGES73
5.2.4.1Stringent regulatory approval process for pharmaceuticals73
5.2.4.2Limited awareness of vaccine coverage73
5.2.4.3Misdiagnosis due to diversity of parasites74
5.2.4.4Low animal healthcare expenditure in emerging markets74
TABLE 9MARKET CHALLENGES: IMPACT ANALYSIS74
 
6INDUSTRY INSIGHTS75
6.1INTRODUCTION75
6.2INDUSTRY TRENDS75
6.2.1RISING ACQUISITIONS OF SMALLER COMPANIES BY GLOBAL PLAYERS75
TABLE 10COMPANION ANIMAL PHARMACEUTICALS MARKET: MAJOR ACQUISITIONS (2017–2022)76
6.2.2INCREASING PRODUCT INNOVATIONS FOR ANIMAL HEALTHCARE76
TABLE 11INNOVATIVE COMPANION ANIMAL PHARMACEUTICAL TRENDS77
6.2.3EXPANDING VETERINARY BUSINESSES WORLDWIDE77
6.3PORTER’S FIVE FORCES ANALYSIS78
TABLE 12PORTER’S FIVE FORCES ANALYSIS78
6.3.1THREAT OF NEW ENTRANTS78
6.3.2THREAT OF SUBSTITUTES79
6.3.3BARGAINING POWER OF SUPPLIERS79
6.3.4BARGAINING POWER OF BUYERS79
6.3.5INTENSITY OF COMPETITIVE RIVALRY79
6.4REGULATORY ANALYSIS80
FIGURE 26COMPANION ANIMAL PHARMACEUTICAL MARKET: DEVELOPMENT AND APPROVAL PROCESS FOR PRODUCTS81
TABLE 13US: RECENT DEVELOPMENTS IN REGULATIONS FOR VETERINARY DRUGS82
FIGURE 27COMPANION ANIMAL PHARMACEUTICAL MARKET: PRODUCT APPROVAL PROCESS IN EUROPE83
6.4.1REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS84
6.4.1.1US84
TABLE 14NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS84
6.4.1.2Europe86
TABLE 15EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS86
6.4.1.3Rest of the World87
TABLE 16REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS87
6.5VALUE CHAIN ANALYSIS87
FIGURE 28COMPANION ANIMAL PHARMACEUTICALS MARKET: VALUE CHAIN ANALYSIS88
6.6SUPPLY CHAIN ANALYSIS88
FIGURE 29COMPANION ANIMAL PHARMACEUTICALS MARKET: SUPPLY CHAIN ANALYSIS90
6.7ECOSYSTEM ANALYSIS90
6.7.1COMPANION ANIMAL PHARMACEUTICALS MARKET: ECOSYSTEM ANALYSIS90
FIGURE 30COMPANION ANIMAL PHARMACEUTICALS MARKET: ECOSYSTEM ANALYSIS91
6.8PATENT ANALYSIS91
6.8.1COMPANION ANIMAL PHARMACEUTICALS MARKET: PATENT ANALYSIS TRENDS91
FIGURE 31PATENT PUBLICATION TRENDS (JANUARY 2013–DECEMBER 2022)91
6.8.2TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR COMPANION ANIMAL PHARMACEUTICALS92
FIGURE 32COMPANION ANIMAL PHARMACEUTICALS MARKET: TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR PATENTS (2017–2022)92
6.8.3JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR COMPANION ANIMAL PHARMACEUTICALS93
FIGURE 33COMPANION ANIMAL PHARMACEUTICAL MARKET: TOP APPLICANT COUNTRIES FOR PATENTS (2017–2022)93
6.9PRICING ANALYSIS93
TABLE 17AVERAGE SELLING PRICES OF COMPANION ANIMAL PHARMACEUTICALS BY APPLICATION (USD)93
6.10KEY CONFERENCES AND EVENTS FROM 2023 TO 202494
TABLE 18COMPANION ANIMAL PHARMACEUTICALS MARKET: CONFERENCES AND EVENTS94
6.11KEY STAKEHOLDERS & BUYING CRITERIA95
6.11.1KEY STAKEHOLDERS IN BUYING PROCESS95
FIGURE 34INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 APPLICATIONS95
TABLE 19INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 APPLICATIONS95
FIGURE 35BUYING CRITERIA96
TABLE 20KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS96
6.12TRADE ANALYSIS96
7COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION97
7.1INTRODUCTION98
TABLE 21COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)98
7.2INFECTIOUS DISEASES98
TABLE 22COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)99
TABLE 23COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)99
7.2.1PARASITICIDES100
7.2.1.1Growing regulatory guidelines to control parasite-related diseases to fuel market100
TABLE 24COMPANION ANIMAL PHARMACEUTICALS MARKET FOR PARASITICIDES, BY COUNTRY, 2020–2027 (USD MILLION)101
7.2.2VACCINES101
7.2.2.1Growing awareness among pet owners for canine & feline vaccines to drive market101
TABLE 25COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION)103
7.2.3ANTIBIOTICS AND ANTIMICROBIALS103
7.2.3.1Effective prevention for clinical and subclinical diseases in companion animals to fuel uptake103
TABLE 26COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ANTIBIOTICS AND ANTIMICROBIALS, BY COUNTRY, 2020–2027 (USD MILLION)104
7.2.4OTHERS105
TABLE 27COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHERS, BY COUNTRY, 2020–2027 (USD MILLION)106
7.3DERMATOLOGIC DISEASES106
7.3.1RISING CASES OF DERMATITIS DUE TO NUTRITIONAL DEFICIENCIES TO DRIVE MARKET106
TABLE 28COMPANION ANIMAL PHARMACEUTICALS MARKET FOR DERMATOLOGIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)107
7.4PAIN108
7.4.1RISING DEMAND FOR ANTI-INFLAMMATORY DRUGS AND OPIOIDS TO DRIVE MARKET108
TABLE 29COMPANION ANIMAL PHARMACEUTICALS MARKET FOR PAIN, BY COUNTRY, 2020–2027 (USD MILLION)109
7.5ORTHOPEDIC DISEASES109
7.5.1GROWING PREVALENCE OF OSTEOARTHRITIS DUE TO INCREASING OBESITY IN PETS TO DRIVE MARKET109
TABLE 30COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)110
7.6BEHAVIORAL DISORDERS110
7.6.1INCREASING AWARENESS AMONG PET OWNERS FOR APPROPRIATE PET BEHAVIOR TO SUPPORT MARKET GROWTH110
TABLE 31COMPANION ANIMAL PHARMACEUTICALS MARKET FOR BEHAVIORAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)111
7.7OTHER INDICATIONS112
TABLE 32COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)113
8COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION114
8.1INTRODUCTION115
TABLE 33ROUTES OF ADMINISTRATION FOR KEY COMPANION ANIMAL PHARMACEUTICALS115
TABLE 34COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)116
8.2ORAL ADMINISTRATION116
8.2.1ABILITY TO TREAT A WIDE RANGE OF DISEASES AND AFFORDABILITY OF MEDICATION TO DRIVE DEMAND116
TABLE 35COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)117
8.3INJECTABLE ADMINISTRATION117
8.3.1ADVANTAGES OF COMPLETE ABSORPTION AND BIOAVAILABILITY TO FUEL MARKET117
TABLE 36COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INJECTABLE ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)118
 
8.4TOPICAL ADMINISTRATION118
8.4.1TEMPORARY EFFECTS OF TOPICAL DRUGS COMPARED TO ORAL AND PARENTERAL DRUGS TO RESTRAIN MARKET118
TABLE 37COMPANION ANIMAL PHARMACEUTICAL MARKET FOR TOPICAL ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)119
9COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE120
9.1INTRODUCTION121
TABLE 38COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)121
9.2DOGS121
9.2.1RISING PET DOG POPULATION WORLDWIDE TO DRIVE MARKET121
FIGURE 36GROWING PET DOG POPULATION IN INDIA (MILLION)122
FIGURE 37POPULATION OF PET DOGS GLOBALLY (MILLION)123
TABLE 39COMPANION ANIMAL PHARMACEUTICALS MARKET FOR DOGS, BY COUNTRY, 2020–2027 (USD MILLION)123
9.3CATS124
9.3.1INCREASING R&D ACTIVITIES ON FELINE HEALTH TO DRIVE MARKET124
TABLE 40COMPANION ANIMAL PHARMACEUTICALS MARKET FOR CATS, BY COUNTRY, 2020–2027 (USD MILLION)125
9.4HORSES125
9.4.1RISING PREVALENCE OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH125
TABLE 41HORSE POPULATION, BY REGION, 2016–2020 (MILLION)126
TABLE 42COMPANION ANIMAL PHARMACEUTICALS MARKET FOR HORSES, BY COUNTRY, 2020–2027 (USD MILLION)127
9.5OTHER COMPANION ANIMALS127
TABLE 43COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER COMPANION ANIMALS, BY COUNTRY, 2020–2027 (USD MILLION)128
10COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL129
10.1INTRODUCTION130
TABLE 44COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)130
10.2VETERINARY HOSPITALS130
10.2.1GROWING FOCUS ON HEALTHCARE AND COMPANION ANIMAL DIAGNOSTIC SERVICES TO DRIVE MARKET130
TABLE 45VETERINARY VISIT EXPENSES FOR CATS AND DOGS (US)131
TABLE 46COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VETERINARY HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION)131
10.3VETERINARY CLINICS132
10.3.1RISING NUMBER OF PRIVATE CLINICAL PRACTICES TO DRIVE MARKET132
TABLE 47NUMBER OF PRIVATE CLINICAL PRACTICES, BY COUNTRY (2019 VS. 2021)132
TABLE 48COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VETERINARY CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)133
10.4RETAIL PHARMACIES134
10.4.1ACCESSIBILITY OF PHARMACEUTICALS THROUGH PRESCRIPTIONS AND OTC MEDICATION TO SUPPORT MARKET GROWTH134
TABLE 49COMPANION ANIMAL PHARMACEUTICALS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2020–2027 (USD MILLION)135
11COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION136
11.1INTRODUCTION137
TABLE 50COMPANION ANIMAL POPULATION, BY COUNTRY, 2022 (THOUSAND)137
FIGURE 38COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHIC SNAPSHOT138
TABLE 51COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION, 2020–2027 (USD MILLION)138
11.2NORTH AMERICA139
FIGURE 39EXPECTED GROWTH FOR NUMBER OF VETERINARIANS IN NORTH AMERICA (2012 VS. 2030)140
11.2.1NORTH AMERICA: RECESSION IMPACT140
FIGURE 40NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET SNAPSHOT141
TABLE 52NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)141
TABLE 53NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)142
TABLE 54NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)142
TABLE 55NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)142
TABLE 56NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)143
TABLE 57NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)143
11.2.2US143
11.2.2.1Rising pet expenditure to fuel market143
FIGURE 41US: POPULATION OF DOGS, 2012–2020 (MILLION)144
FIGURE 42US: EXPENDITURE ON VET VISITS, 2013–2020144
TABLE 58US: PRIVATE CLINICAL PRACTICES, BY ANIMAL TYPE, 2019–2021144
TABLE 59US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)145
TABLE 60US: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)145
TABLE 61US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)145
TABLE 62US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)146
TABLE 63US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)146
11.2.3CANADA146
11.2.3.1Increasing pet ownership rates to drive demand for vaccines146
TABLE 64CANADA: COMPANION ANIMAL POPULATION, 2016–2020 (MILLION)147
TABLE 65CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)147
TABLE 66CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)147
TABLE 67CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)148
TABLE 68CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)148
TABLE 69CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)148
11.3EUROPE149
TABLE 70EUROPE: COMPANION ANIMAL POPULATION, 2021 (MILLION)149
TABLE 71EUROPE: NUMBER OF VETERINARIANS, 2014–2020150
11.3.1EUROPE: RECESSION IMPACT150
TABLE 72EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)150
TABLE 73EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)151
TABLE 74EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)151
TABLE 75EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)151
TABLE 76EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)152
TABLE 77EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)152
11.3.2GERMANY152
11.3.2.1Rising focus on animal health due to increasing vet practices to drive market152
TABLE 78GERMANY: COMPANION ANIMAL POPULATION, 2016–2021 (MILLION)153
TABLE 79GERMANY: NUMBER OF VETERINARIANS, 2015 VS. 2020153
TABLE 80GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)153
TABLE 81GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)154
TABLE 82GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)154
TABLE 83GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)154
TABLE 84GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)155
 
11.3.3UK155
11.3.3.1Availability of animal health insurance policies to fuel market for pharmaceuticals155
TABLE 85UK: COMPANION ANIMAL POPULATION, 2017–2020 (MILLION)155
TABLE 86UK: NUMBER OF VETERINARIANS, 2016 VS. 2020156
TABLE 87UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)156
TABLE 88UK: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)156
TABLE 89UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)157
TABLE 90UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)157
TABLE 91UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)157
11.3.4FRANCE158
11.3.4.1Rising prevalence of infectious diseases to drive demand for animal health products158
TABLE 92FRANCE: COMPANION ANIMAL POPULATION, 2010–2021 (MILLION)158
TABLE 93FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)159
TABLE 94FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)159
TABLE 95FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)159
TABLE 96FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)160
TABLE 97FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)160
11.3.5SPAIN160
11.3.5.1Increasing adoption rates of dogs and cats to fuel market160
TABLE 98SPAIN: COMPANION ANIMAL POPULATION, 2016–2021 (MILLION)161
TABLE 99SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)161
TABLE 100SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)161
TABLE 101SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)162
TABLE 102SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)162
TABLE 103SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)162
11.3.6ITALY163
11.3.6.1Lucrative animal and pet health sectors to drive market growth163
TABLE 104ITALY: PET POPULATION, 2017–2021 (MILLION)163
TABLE 105ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)163
TABLE 106ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)164
TABLE 107ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)164
TABLE 108ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)164
TABLE 109ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)165
11.3.7REST OF EUROPE165
TABLE 110REST OF EUROPE: COMPANION ANIMAL OWNERSHIP, 2018 (MILLION)165
TABLE 111REST OF EUROPE: NUMBER OF VETERINARIANS AND PARAVETERINARIANS, 2019 VS. 2020166
TABLE 112REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)166
TABLE 113REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)167
TABLE 114REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)167
TABLE 115REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)167
TABLE 116REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)168
11.4ASIA PACIFIC168
11.4.1ASIA PACIFIC: RECESSION IMPACT168
FIGURE 43ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET SNAPSHOT169
TABLE 117ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)170
TABLE 118ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)170
TABLE 119ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)170
TABLE 120ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)171
TABLE 121ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)171
TABLE 122ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)171
11.4.2CHINA172
11.4.2.1Rising number of zoonotic & infectious diseases in animals to drive market172
FIGURE 44CHINA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION)173
TABLE 123CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)173
TABLE 124CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)174
TABLE 125CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)174
TABLE 126CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)174
TABLE 127CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)175
11.4.3JAPAN175
11.4.3.1Rising demand for imported breeds to support market growth175
TABLE 128JAPAN: DOMESTICATED DOG AND CAT POPULATION, 2012–2020 (THOUSAND)175
TABLE 129JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)176
TABLE 130JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)176
TABLE 131JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)176
TABLE 132JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)177
TABLE 133JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)177
11.4.4INDIA177
11.4.4.1Rising focus on pet care due to a large population of domesticated animals to drive market177
FIGURE 45INDIA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION)178
TABLE 134INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)178
TABLE 135INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)179
TABLE 136INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)179
TABLE 137INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)179
TABLE 138INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)180
11.4.5SOUTH KOREA180
11.4.5.1Pet care initiatives for street dogs and cats to fuel market for animal care products180
TABLE 139SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)181
TABLE 140SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)181
TABLE 141SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)181
TABLE 142SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)182
TABLE 143SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)182
 
11.4.6AUSTRALIA182
11.4.6.1Growing awareness of parasitic infections to drive demand for parasiticides182
FIGURE 46AUSTRALIA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION)183
TABLE 144AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)183
TABLE 145AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)184
TABLE 146AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)184
TABLE 147AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)184
TABLE 148AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)185
11.4.7REST OF ASIA PACIFIC185
TABLE 149REST OF ASIA PACIFIC: NUMBER OF VETERINARIANS, 2012−2021185
TABLE 150REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)186
TABLE 151REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)186
TABLE 152REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)186
TABLE 153REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)187
TABLE 154REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)187
11.5LATIN AMERICA187
11.5.1GROWING POOL OF SKILLED VETERINARIANS OWING TO RISING PET POPULATION TO DRIVE MARKET187
TABLE 155NUMBER OF VETERINARIANS AND VETERINARY PARA-PROFESSIONALS IN LATIN AMERICA (2016 VS. 2019)188
11.5.2LATIN AMERICA: RECESSION IMPACT188
TABLE 156LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)189
TABLE 157LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)189
TABLE 158LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)189
TABLE 159LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)190
TABLE 160LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)190
11.6MIDDLE EAST & AFRICA190
11.6.1EMERGING MARKET FOR ANIMAL HEALTHCARE PRACTISES TO SUPPORT UPTAKE190
11.6.2MIDDLE EAST & AFRICA: RECESSION IMPACT191
TABLE 161MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)191
TABLE 162MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)192
TABLE 163MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)192
TABLE 164MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)192
TABLE 165MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)193
12COMPETITIVE LANDSCAPE194
12.1OVERVIEW194
FIGURE 47KEY PLAYER STRATEGIES ADOPTED BY MARKET PLAYERS (2019–2022)195
12.2REVENUE SHARE ANALYSIS OF TOP FIVE PLAYERS195
FIGURE 48COMPANION ANIMAL PHARMACEUTICALS MARKET: REVENUE SHARE ANALYSIS OF TOP FIVE PLAYERS (2017–2021)196
12.3MARKET SHARE ANALYSIS196
FIGURE 49COMPANION ANIMAL PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER (2021)197
12.4COMPANY EVALUATION QUADRANT198
12.4.1STARS198
12.4.2EMERGING LEADERS199
12.4.3PERVASIVE PLAYERS199
12.4.4PARTICIPANTS199
FIGURE 50COMPANION ANIMAL PHARMACEUTICALS MARKET: COMPANY EVALUATION QUADRANT (2021)200
12.5EVALUATION QUADRANT FOR STARTUPS/SMES200
12.5.1PROGRESSIVE COMPANIES200
12.5.2DYNAMIC COMPANIES201
12.5.3STARTING BLOCKS201
12.5.4RESPONSIVE COMPANIES201
FIGURE 51COMPANION ANIMAL PHARMACEUTICALS MARKET: STARTUPS/SME EVALUATION QUADRANT (2021)201
12.6COMPETITIVE BENCHMARKING202
TABLE 166COMPANION ANIMAL PHARMACEUTICALS MARKET: INDICATION PORTFOLIO ANALYSIS:202
TABLE 167COMPANION ANIMAL PHARMACEUTICALS MARKET: ROUTE OF ADMINISTRATION PORTFOLIO ANALYSIS203
TABLE 168COMPANION ANIMAL PHARMACEUTICALS MARKET: ANIMAL TYPE PORTFOLIO ANALYSIS205
TABLE 169COMPANION ANIMAL PHARMACEUTICALS MARKET: DISTRIBUTION CHANNEL PORTFOLIO ANALYSIS206
12.7COMPANY GEOGRAPHIC FOOTPRINT207
TABLE 170COMPANION ANIMAL PHARMACEUTICALS MARKET: REGIONAL REVENUE MIX207
 
12.8COMPETITIVE SITUATION AND TRENDS208
12.8.1PRODUCT LAUNCHES & APPROVALS208
TABLE 171PRODUCT LAUNCHES & APPROVALS208
12.8.2DEALS210
TABLE 172DEALS210
12.8.3OTHER DEVELOPMENTS213
TABLE 173OTHER DEVELOPMENTS213
13COMPANY PROFILES214
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1KEY PLAYERS214
13.1.1ZOETIS INC.214
TABLE 174ZOETIS INC.: BUSINESS OVERVIEW214
FIGURE 52ZOETIS: COMPANY SNAPSHOT (2021)215
13.1.2MERCK & CO., INC.219
TABLE 175MERCK & CO., INC.: BUSINESS OVERVIEW219
FIGURE 53MERCK & CO., INC.: COMPANY SNAPSHOT (2021)220
13.1.3BOEHRINGER INGELHEIM INTERNATIONAL GMBH224
TABLE 176BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW224
FIGURE 54BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT (2021)225
13.1.4ELANCO ANIMAL HEALTH INCORPORATED229
TABLE 177ELANCO ANIMAL HEALTH INCORPORATED: BUSINESS OVERVIEW229
FIGURE 55ELANCO ANIMAL HEALTH INCORPORATED: COMPANY SNAPSHOT (2021)230
13.1.5VIRBAC234
TABLE 178VIRBAC: BUSINESS OVERVIEW234
FIGURE 56VIRBAC: COMPANY SNAPSHOT (2021)235
13.1.6DECHRA PHARMACEUTICALS PLC238
TABLE 179DECHRA PHARMACEUTICALS PLC: BUSINESS OVERVIEW238
FIGURE 57DECHRA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2021)239
13.1.7VETOQUINOL243
TABLE 180VETOQUINOL: BUSINESS OVERVIEW243
FIGURE 58VETOQUINOL: COMPANY SNAPSHOT (2021)244
13.1.8NEOGEN CORPORATION247
TABLE 181NEOGEN CORPORATION: BUSINESS OVERVIEW247
FIGURE 59NEOGEN CORPORATION: COMPANY SNAPSHOT (2021)247
13.1.9ORION GROUP249
TABLE 182ORION GROUP: BUSINESS OVERVIEW249
FIGURE 60ORION GROUP: COMPANY SNAPSHOT (2021)250
13.1.10ECO ANIMAL HEALTH GROUP PLC252
TABLE 183ECO ANIMAL HEALTH GROUP PLC: BUSINESS OVERVIEW252
FIGURE 61ECO ANIMAL HEALTH GROUP PLC: COMPANY SNAPSH